搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
1 天
AbbVie’s Parkinson’s Drug Tavapadon: A Market Perform Rating Amidst Competitive ...
Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...
Becker's Hospital Review
1 天
AbbVie drug shows promise in treating Parkinson's: 3 notes
The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson's disease. Patients receiving the drug at doses of 5 ...
BioSpace
2 天
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...
STAT
2 天
Biotech’s real estate market is still upside down
Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...
2 天
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three ...
McKnight's Long-Term Care News
2 天
Promising results from Parkinson’s drug trial
Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's ...
The Pharma Letter
2 天
AbbVie’s tavapadon offers encouragement in Parkinson’s
AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...
devdiscourse
2 天
Current Updates: Major Developments in Health Sector
This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...
Monthly Prescribing Reference
2 天
Tavapadon Improves Motor Function in Patients With Early Parkinson Disease
In the TEMPO-1 trial, participants with early PD were randomly assigned to receive tavapadon 5mg or 15mg once daily or placebo.
2 天
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...
3 天
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With ...
AbbVie Inc (NYSE:ABBV) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in ...
3 天
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
The trial studied two doses of the drug, tavapadon, as a monotherapy in which patients showed a statistically significant ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈